Exhibit 5

State of California ex. rel. Ven-A-Care of the Florida Keys, Inc. v. Abbott Laboratories, Inc., et al.

Exhibit to the Declaration of Matthew C. Kilman in Support of Plaintiffs' Opposition to Mylan's Motion for Partial Summary Judgment

February 21, 2008

Page 1

UNITED STATES DISTRICT COURT

DISTRICT OF MASSACHUSETTS

THE COMMONWEALTH :

OF MASSACHUSETTS

Plaintiff :

MYLAN, INC., IVAX : C.A. NO. 03-11865-PBS

CORPORATION, WARRICK :

PHARMACEUTICALS

CORPORATION, WATSON :

PHARMACEUTICALS, INC.,

SCHEIN PHARMACEUTICAL, INC., :

TEVA PHARMACEUTICALS USA, INC., :

PAR PHARMACEUTICAL, INC.,

PUREPAC PHARMACEUTICAL, INC., :

PUREPAC PHARMACEUTICAL CO., :

and ROXANE LABORATORIES, INC. :

Defendants :

Videotape deposition of Roderick Jackson

Thursday, February 21, 2008

* * *

February 21, 2008

	Page 2
1	* * *
2	Videotaped Deposition of Roderick Jackson
3	Thursday, February 21, 2008
4	* * *
5	a witness herein, taken on behalf of the Plaintiff in
6	the above-entitled cause of action pursuant to notice
7	and the Federal Rules of Civil Procedure, by and
8	before Kathy D. Landock, Notary Public and Registered
9	Merit Reporter in and for the State of West Virginia,
10	at Streski Reporting & Video Service, WesMon Center
11	IV 829 Fairmont Road, Suite 101, Morgantown, West
12	Virginia 26501, commencing at 10:06 a.m.
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	

- 1 Christi with them and was transferred to Houston,
- ² Texas. I was with them less than a year because I
- wanted to get back to Corpus Christi.
- 4 On my arrival in Corpus Christi, and I
- 5 can't tell you specifically what time that was, I
- obtained a job with Southwestern Wholesale Drug. I
- was with them about five and a half years, six
- years, somewhere in there.
- I had a brief stint where a gentleman and
- 10 I bought some franchise food companies, one was a
- company by the name of Der Weinersnitzel and the
- other was a Taco Bell. And I was in that for not a
- long time, unfortunately my partner died of a heart
- attack and I liquidated the business, I'm going to
- quess somewhere around 1968.
- I then had a brief stint of three months
- looking for a job, but I worked with a company
- called Madison Chemical out of Chicago and then
- obtained what I would call full-time employment
- 20 with Lederle Laboratories in the latter part, I
- believe it was 1968. I was with Lederle until
- 22 March of 1986. And from 1986 until May 1 of 2002 I

- was with Mylan Laboratories.
- I retired on that date, May 1 of 2002,
- stayed retired about three and a half years and
- 4 have recently gone back to work on a somewhat
- 5 limited basis with a company called Cobalt
- 6 Laboratories.
- Q. Let me go back for a second and just ask
- you about a couple of your jobs.
- 9 When you were with Southwest Wholesale
- Drug, what was their business?
- A. It was a wholesale distribution company
- that was eventually acquired by Bergen, Brunswick
- sometime after I left the company, but it was a
- similar company to McKesler Cardinal, those type
- companies.
- Q. What was your position with Southwest
- Wholesale Drug?
- A. I had a number of them. Do you want them
- ¹⁹ all?
- Q. If you would.
- A. I started in the warehouse on the
- receiving dock. I went from that to putting the

- ¹ A. Yes.
- Q. So I think you said you joined Mylan in
- March of '86?
- ⁴ A. That's correct.
- Q. What was your position when you joined?
- ⁶ A. Vice-president of marketing and sales.
- Q. How long do you hold the position of
- vice-president of marketing and sales?
- ⁹ A. Until 1992.
- Q. What happens in 1992?
- 11 A. Then I was promoted to senior
- vice-president of the company.
- Q. Still with responsibility for marketing
- and sales?
- 15 A. That was part of the job at that point,
- yes.
- Q. What other, if any, duties or
- responsibilities do you assume in '92?
- A. In '92 I took over -- not took over, but
- created business development and then became very
- entrenched in strategic planning and strategic
- direction for the company.

- A. As far as the price changes, as I
- remember it on Lorazepam, I made the changes on the
- price, the selling price.
- As far as any other, you know, peripheral
- prices around AWP or whatever else, that would have
- 6 come through Tom.
- Q. Maybe it's helpful to clarify a little
- bit. When you say selling price, you're referring
- ⁹ to the contract price, the actual transaction
- between Mylan and its customer; is that right?
- MR. ESCOBAR: Objection to the form.
- A. Again, you seem to want to mix things. A
- contract price I did not set, I would not have set
- the contract price. The price that I wanted the
- product sold for at that time, as I call it the
- re-launch, I set that price.
- BY MR. MULLIN:
- Q. You've referred to selling price. Is
- there also something called the WAC price?
- A. There are occasions when a WAC price is
- used. I'm not sure if we used them on everything
- or not.

Page 88 That was my understanding. Α. MR. ESCOBAR: Objection to the form. BY MR. MULLIN: With regard to the WAC and AWP prices, is Ο. it fair to say that you supervised the people that set the WAC and AWP prices in connection with the Lorazepam price change, 1998 price changes? Objection to the form. MR. ESCOBAR: I would have been their direct report or Α. 10 indirect report. 11 BY MR. MULLIN: 12 Well, I think you said it was Tom was the Ο. 13 quy; right? 14 Α. Tom was the quy. 15 So that you were his direct report? Ο.

- A. According to this organizational chart.
- As I said, functionally I don't think we were
- operating that way.
- MR. MULLIN: Let's mark this as our
- next exhibit.
- 21 * * *
- (Whereupon, Exhibit Jackson 004 was

Page 89 1 marked for identification purposes.) 2 BY MR. MULLIN: I'm showing you what has been marked as Ο. Exhibit No. 4. This is another one of those tables of organization that was produced to us by the company. You'll notice that on the first page, lower left-hand corner it says as of September 29, 199. 10 Do you see that? 11 Α. Yes. 12 Mr. Puskar is at the top and you're 13 listed as the senior vice-president, Mylan 14 Laboratories, Inc.; right? 15 Α. Yes. 16 If you flip to page 2 of Exhibit No. 4, 17 essentially there is Mr. DeBone, Lou DeBone is 18 senior vice-president and it has Mylan 19 Pharmaceuticals reporting to him; is that right? 20 Α. That's what it says. 21 And below that there's various boxes and 22 entities, none of which indicate sales and

Page 90 right?

Third page of locument is reting right?

This 29, '99; right?

- marketing responsibilities; is that right?
- 2 A. That's correct.
- Q. Then if you turn to the third page of
- Exhibit No. 4, the heading on the document is
- business development, sales and marketing
- ⁶ administration, Mylan Laboratories; right?
- A. Yes.
- Q. And you're at the head of this
- organization chart as of September 29, '99; right?
- A. Yes.
- Q. And you've got Hal Korman VP sales and
- marketing reporting to you; right?
- ¹³ A. Yes.
- 0. And at that time Hal would have been the
- VP sales at Mylan Pharmaceuticals?
- ¹⁶ A. Yes.
- Q. And over on the far right-hand side
- you've got Tom Darby, VP pricing contracts and
- admin reporting directly to you?
- A. That's correct.
- Q. And is that consistent with your
- recollection that for a number of years both Korman

- and Darby reported directly to you?
- A. From an organizational standpoint, this
- 3 chart, that is correct. From a functional
- standpoint, Tom and Hal were hand in hand, that's
- ⁵ how they did -- they made all the decision. The
- only time I was involved is when they thought my
- input would be necessary.
- But from a functional standpoint, despite
- what this chart says, that's just not how we
- operated it.
- Q. And essentially this chart, page 3 of
- Exhibit No. 4, it shows Bill Richardson being the
- president of Bertek and reporting to you; correct?
- A. That's correct.
- Q. Was that true?
- A. Yes.
- 17 Q. That's the way you operated?
- A. Yes.
- 19 Q. To the extent that Bertek published any
- prices to price reporting services, who was
- determining Bertek's prices?
- A. That would have been Bill and David

February 21, 2008

Page 107

- ¹ are.
- ² Q. Do you have a recollection in February of
- ³ 1998 Mylan announced some price changes with regard
- to Lorazepam and Chlorazapate?
- ⁵ A. Yes.
- ⁶ Q. I'm focused on the period just prior to
- ⁷ that.
- 8 A. That would be '97.
- 9 Q. Second half of '97.
- A. Okay, now what was the question?
- Q. Were you having any supply problems with
- ¹² API in late '97?
- MR. ESCOBAR: Objection to the form
- and no foundation.
- A. I remember there was some discussions
- about supply problems on some drugs. I don't
- remember if this was the one or not. It's too long
- ago for me to remember today.
- 19 BY MR. MULLIN:
- Q. In 1997, did you do a review of Mylan's
- product line to identify drugs that might be
- amenable to price increases?

6

8

16

17

18

19

20

21

22

February 21, 2008

Page 108

- A. Yes, I did. I personally did that.
- Q. And what were the criteria that you used in identifying drugs that might be susceptible or
- 4 amenable to price increase?
 - A. We had done -- we being the sales and marketing area -- had done several reviews of products and their contribution or lack of contribution to the income statement.

Pand in that process I also requested a review to see who we were competing with on some of these products, because again, on a day-to-day basis I had gotten quite far away and had relied on the staff that I have indicated to you, which were either Hal Korman and Tom Darby or whomever was in that job at whatever time.

And in that review it became apparent to me that we had some products that were not doing very well. And as I looked, particularly on some of them, much to my surprise, I found that we were handling these products as if there were multitudes of competitors in the marketplace, where in fact in some of these products we were the only company